TSE:PLI - ProMetic Life Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.41 +0.02 (+5.13 %)
(As of 11/20/2018 04:00 PM ET)
Previous CloseC$0.39
Today's RangeC$0.39 - C$0.43
52-Week RangeC$0.36 - C$1.80
Volume1.34 million shs
Average Volume1.25 million shs
Market CapitalizationN/A
P/E Ratio-2.44
Dividend YieldN/A
BetaN/A
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Receive PLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:PLI
Previous Symbol
CUSIPN/A
Phone+1-450-7810115

Debt

Debt-to-Equity Ratio140.42
Current Ratio1.45
Quick Ratio0.66

Price-To-Earnings

Trailing P/E Ratio-2.44
Forward P/E Ratio-4.05
P/E GrowthN/A

Sales & Book Value

Annual SalesC$55.08 million
Price / Sales5.35
Cash FlowC$0.02 per share
Price / Cash24.38
Book ValueC$0.08 per share
Price / Book5.06

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares718,127,000
Market CapC$0.00
OptionableNot Optionable

ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."

When is ProMetic Life Sciences' next earnings date?

ProMetic Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for ProMetic Life Sciences.

What price target have analysts set for PLI?

4 analysts have issued 12 month target prices for ProMetic Life Sciences' stock. Their forecasts range from C$0.60 to C$2.00. On average, they anticipate ProMetic Life Sciences' share price to reach C$1.04 in the next year. This suggests a possible upside of 153.7% from the stock's current price. View Analyst Price Targets for ProMetic Life Sciences.

What is the consensus analysts' recommendation for ProMetic Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.

Has ProMetic Life Sciences been receiving favorable news coverage?

News coverage about PLI stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProMetic Life Sciences earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the near term.

Who are some of ProMetic Life Sciences' key competitors?

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the folowing people:
  • Mr. Pierre Laurin, Pres, CEO & Non-Independent Director (Age 57)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 64)
  • Dr. John Moran, Chief Medical Officer (Age 72)

How do I buy shares of ProMetic Life Sciences?

Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ProMetic Life Sciences' stock price today?

One share of PLI stock can currently be purchased for approximately C$0.41.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is http://prometic.com/.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.


MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  529
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel